50至70岁早期乳腺癌患者省略前哨淋巴结活检:将更新版ASCO指南应用于真实世界人群
单中心回顾性队列研究纳入2022至2024年268例符合2025年ASCO指南省略前哨淋巴结活检(SLNB)标准的50至70岁早期浸润性乳腺癌患者,SLN阳性率仅5.6%,SLN阳性结果仅可能影响4.1%患者的辅助治疗推荐,>95%患者辅助治疗推荐未改变。
要点
- 符合2025年ASCO指南SLNB省略标准的50至70岁患者中,SLN阳性率为5.6%。
- SLN阳性结果仅可能影响4.1%患者的辅助治疗推荐,>95%患者辅助治疗未改变。
- 病理肿瘤分期(P=.006)和21基因复发评分(P<.001)与SLN阳性显著相关。
核心结论
- 在符合2025年ASCO指南SLNB省略标准的50至70岁早期乳腺癌患者中,SLN阳性不常见,且>95%患者辅助治疗推荐未因SLN结果改变,部分归因于复发评分等其他因素提供的信息。
研究设计与样本
- 单中心回顾性队列研究,纳入2022至2024年50至70岁早期浸润性乳腺癌(cT1N0、1-2级、雌激素受体阳性、HER2阴性)且接受SLNB的患者,共268例符合新ASCO指南标准,术前腋窝超声非必需。
主要发现
- 268例患者平均年龄62岁(SD,5.1),81.0%为导管组织学,94.8%为病理T1期,51.5%为1级。
- SLN阳性15例(5.6%),其中8例pN1mi、7例pN1a。
- 与SLN阳性显著相关的因素包括病理肿瘤分期(P=.006)和21基因复发评分(P<.001)。
- SLN阳性结果可能影响11例(4.1%)患者的辅助治疗推荐:1例低21基因复发评分者接受化疗,1例接受CDK4/6抑制剂,9例符合部分乳腺放疗条件者接受了全乳放疗。
- 中位随访24.0个月,2年无病生存率为98%(95%CI,96.1%-99.9%)。
关键数值与推荐
- 2025年ASCO指南推荐对50岁以上早期乳腺癌患者省略SLNB。
- 辅助治疗包括内分泌治疗(86.9%)、全乳放疗(73.1%)、部分乳腺放疗(19.4%)、化疗(5.6%)和CDK4/6抑制剂(0.7%)。
临床怎么用
- 对符合2025年ASCO指南标准的50至70岁早期乳腺癌患者,可考虑省略SLNB,因SLN阳性率低且极少改变辅助治疗决策。
- 病理肿瘤分期和21基因复发评分与SLN阳性相关,可作为是否省略SLNB的参考因素。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Recent practice-changing guidelines from the American Society of Clinical Oncology (ASCO) recommend the omission of sentinel lymph node biopsy (SLNB) in patients over the age of 50 with early-stage breast cancer. We aimed to evaluate the association of clinicopathologic factors with sentinel lymph node positivity (SLN+) and the association of SLN+ with adjuvant therapy recommendation in this population. METHODS AND MATERIALS: A single-institution retrospective cohort study of patients aged 50 to 70 years with early-stage invasive breast cancer (cT1N0, grade 1-2, estrogen receptor-positive, human epidermal growth factor receptor 2 negative (HER2-)) between 2022 and 2024 who underwent SLNB. Preoperative axillary ultrasound was not required. The univariate relationship between covariates and SLN+ was assessed using Fisher's exact test or logistic regression, followed by multivariable logistic regression. Fisher's exact test was also used to evaluate the relationship between SLN+ and receipt of adjuvant therapy. Two-year disease-free survival was estimated using the Kaplan-Meier method. RESULTS: Among 268 patients meeting the new ASCO Guideline criteria, the average age was 62 years (SD, 5.1). The majority had ductal histology (81.0%), pathologic T1 disease (94.8%), and grade 1 disease (51.5%). Adjuvant therapy included endocrine therapy (86.9%), whole breast radiation therapy (WBRT) (73.1%), partial breast radiation therapy (19.4%), chemotherapy (5.6%), and cyclin-dependent kinase 4/6 inhibitor (0.7%). SLN was positive in 15 (5.6%) patients (8 pN1mi, 7 pN1a). Factors statistically significantly associated with SLN+ included pathologic tumor category (P = .006) and 21-gene recurrence score (P < .001). An SLN+ result potentially impacted adjuvant recommendations for 11 patients (4.1%): 1 with a low 21-gene recurrence score received chemotherapy, 1 received a cyclin-dependent kinase 4/6 inhibitor, and 9 were eligible for partial breast radiation and received WBRT. With a median follow-up of 24.0 months, 2-year disease-free survival was 98% (95% CI, 96.1%-99.9%). CONCLUSIONS: In patients aged 50 to 70 years meeting the 2025 ASCO Guideline for SLNB omission, SLN+ was infrequent. Adjuvant treatment recommendations were unchanged in >95% of patients, due in part to information from other factors, such as recurrence score.
引用
- Namoglu EC, Flanagan MR, Teles MS, et al. Omission of Sentinel Lymph Node Biopsy Among Women Aged 50 to 70 With Early-Stage Breast Cancer: Applying an Updated ASCO Guideline to a Real-World Population. Pract Radiat Oncol. 2026. PMID: 42409317. doi:10.1016/j.prro.2026.06.005
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。